Life Biosciences has raised $80 million in a fully subscribed Series D round as its lead partial-reprogramming program enters human testing. The financing is notable because it moves the company beyond a compelling laboratory story and into the costly period when manufacturing, trial execution and long-term safety become decisive.
Company development at a glance
- Event: $80 million Series D financing announced April 8, 2026.
- Stated runway: Operations into the second half of 2027.
- Lead program: ER-100 for open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.
- Evidence level: Company financing plus an active Phase 1 safety trial. No human efficacy results are available.
What the money is intended to fund
Life Biosciences says the proceeds will support completion of the recently initiated Phase 1 study of ER-100 and continued development of candidates from its partial epigenetic reprogramming platform. The stated runway into late 2027 is meaningful because gene-therapy trials require specialized manufacturing, clinical sites, monitoring and regulatory work long before they can generate an efficacy signal.
Financing does not validate the therapy. It does, however, reduce a near-term operational risk: the possibility that a program reaches the clinic without enough capital to execute the early study and prepare the next steps.
What ER-100 is testing
ER-100 uses a modified adeno-associated virus vector to deliver OCT4, SOX2 and KLF4, three transcription factors collectively called OSK, to one eye. Oral doxycycline is used for 56 days to activate expression. The goal is partial reprogramming: shifting age-related cellular regulation without erasing cell identity.
The open-label, nonrandomized Phase 1 trial plans to enroll up to 18 adults aged 40 to 85. Twelve participants have open-angle glaucoma and six have non-arteritic anterior ischemic optic neuropathy. The glaucoma arm includes low and high doses with sentinel dosing and safety review. Participants are followed for five years.
What the trial can and cannot establish
The principal questions are safety and tolerability. Investigators are monitoring adverse events, eye examinations, laboratory measures, vector distribution and viral shedding. Visual outcomes are being collected, but a small uncontrolled trial cannot establish that ER-100 restores vision or reverses aging in people.
The five-year follow-up reflects the seriousness of an inducible gene therapy. Researchers must watch for inflammation, unintended cell-state changes, loss of control over expression and other delayed effects. The eye offers a localized and closely observable starting point, but it does not eliminate biological risk.
The investment case and the scientific risk
Investors are funding a platform with potential applications beyond optic neuropathy. That platform value depends on whether OSK delivery can be controlled, manufactured consistently and adapted to other tissues. Even a clean Phase 1 result would be an early milestone rather than confirmation of broad rejuvenation.
The next meaningful disclosures will be enrollment progress, dose-limiting toxicities, evidence that the vector remains appropriately localized and any carefully interpreted functional signal. Company announcements should be checked against the trial registry and, eventually, peer-reviewed results.
The Lifespan Brief assessment
The financing gives Life Biosciences the resources to test one of longevity biotechnology’s most consequential ideas in humans. That makes the company worth following. The correct threshold for belief remains clinical evidence. For now, the milestone is that partial reprogramming has reached a monitored safety trial with funding to continue, not that rejuvenation has been demonstrated.